Your Vision, Our Focus
Cerba Research’s clients are supported from pre-clinical to post-market authorization thanks to our in-depth biologics and biosimilars experience. We offer long-standing scientific expertise in pharmacokinetics (PK) and immunogenicity (antibody-drug antibodies (ADAs) and neutralizing antibodies (NAbs)) with a standardized or a customized approach to reflect your vision. Our focus extends from cell and gene therapy, to engineered proteins (including glycoPEGylated proteins (PEG)), monoclonal antibodies (mAb), antibody-drug conjugates (ADCs) and virus-like drug conjugates (VDC). In addition, we are compliant with good laboratory practice (GLP), college of American pathologists (CAP), and clinical laboratory improvement amendments (CLIA), among others for your regulatory requirements.